Investigates dipyridamole's impact on inflammatory markers in rats, suggesting therapeutic potential.
Background: Airway inflammation is often caused by pathogens or exposure to pollutants toxins, allergens, and irritants. The lungs are vital organs and excessive inflammation can be life-threatening. Treatment with anti-inflammatory drugs is essential. Objective: This study aims to investigate the anti-inflammatory activity of dipyridamole (DP) to improve inflammatory events associated with airway inflammation. Materials and Methods: A total of 24 healthy male rats were weighting (150–300 g), which are divided into four groups, each group consists of six rats. Group A: rats were administered distilled water orally, which is considered a control group. Group B: rats were administered distilled water orally with sensitization (by ovalbumin), which is considered a positive control group. Group C: rats were administrated (26.4 mg/kg) DP orally with sensitization. Group D: rats were administrated prednisolone (4.12 mg/kg) orally with sensitization. Results: The results revealed that there was a significant reduction ( P < 0.05) of rat serum levels of interleukin (IL)-6 and tumor necrosis factor-alpha for groups C and D when compared with ova-sensitized positive control (group B). Regarding rat serum levels of IL-4 for groups C and D were reduced, but group C was non-significant ( P > 0.05) when compared with ova sensitize positive (group B). In addition, group C was non-significant elevated ( P > 0.05). IL-10 level in rat serum when compared with ova sensitize positive (group B) but group D was significant. Conclusion: This study concludes that DP has an anti-inflammatory effect in the airway sensitization model as it reduces inflammatory cytokines levels in rat serum.
No takes yet. Share an insight, caveat, or question.
Nashmi et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: